Hurry Up And Approve: EMA Brings Vaccine Decision Forward After Political Pressure

German Health Minister Speaks Out

Resurgence of the coronavirus across Europe made the approval of Pfizer/BioNTech vaccine and the start of immunization programs more urgent.

European Medicines Agency, Amsterdam
The European Medicines Agency has responded to pressure to act faster, bringing forward its ruling to 21 December.

The European Medicines Agency looks set to recommend conditional marketing approval for the first COVID-19 vaccine early next week after public calls from politicians for a faster decision.

The EMA had scheduled a decision on Pfizer/BioNTech’s BNT162b2 by 29 December “at the latest” but has now brought...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Clinical Trials

More from R&D

  • India Tightens Oversight Of CROs With Mandatory Registration

     
    • By 

    Contract research organizations (CROs) in India must gear up to comply with new registration requirements coming into effect in April 2025 that aim to enhance the quality and integrity of clinical trials, as well as of any bioavailability and bioequivalence studies conducted by them.

  • Clinical Trial Diversity Action Plans Need Timely FDA Feedback, Groups Say

     
    • By 

    The agency also should explain the potential consequences for sponsors if enrollment goals are not met, stakeholders say in comments on the DAP draft guidance. Some commenters urged the FDA to apply waiver criteria flexibly, especially for rare diseases.

  • How To Decarbonize Pharma R&D

     

    As the planet heats up and sea levels rise, the need to reduce carbon emissions is becoming ever more urgent. The life sciences industry is just one of many that are looking to cut the carbon it produces.